Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial

被引：167

作者：

Huober, J. ^{[1
,5
]}

Fasching, P. A. ^{[2
,14
]}

Barsoum, M. ^{[3
]}

Petruzelka, L. ^{[4
]}

Wallwiener, D. ^{[5
]}

Thomssen, C. ^{[6
]}

Reimer, T. ^{[7
]}

Paepke, S. ^{[8
]}

Azim, H. A. ^{[9
]}

Ragosch, V. ^{[10
]}

Kubista, E. ^{[11
]}

Baumgaertner, A. K. ^{[8
]}

Beckmann, M. W. ^{[2
]}

May, C. ^{[12
]}

Nimmrich, I. ^{[12
]}

Harbeck, N. ^{[8
,13
]}

机构：

[1] Kantonsspital, Breast Ctr, CH-9007 St Gallen, Switzerland

[2] Univ Erlangen Nurnberg, Dept Gynaecol, D-91054 Erlangen, Germany

[3] Cairo Univ, Natl Canc Inst, Cairo, Egypt

[4] Univ Hosp Prague, Dept Oncol, Prague, Czech Republic

[5] Univ Tubingen, Dept Obstet & Gynaecol, Tubingen, Germany

[6] Univ Halle Wittenberg, Dept Gynaecol, Halle, Saale, Germany

[7] Univ Rostock, Dept Obstet & Gynaecol, Rostock, Germany

[8] Tech Univ Munich, Frauenklin Rechts Isar, Munich, Germany

[9] Cairo Univ, Fac Med, Dept Clin Oncol, Cairo, Egypt

[10] Asklepios Klin Altona, Dept Gynaecol, Hamburg, Germany

[11] Med Univ Vienna, Dept Gynaecol, Vienna, Austria

[12] Novartis Pharrna GmbH BU Oncol, Nurnberg, Germany

[13] Univ Cologne, Breast Ctr, Dept OB&GYN, D-50931 Cologne, Germany

[14] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA

来源：

BREAST | 2012年 / 21卷 / 01期

关键词：

Metastatic breast cancer; Endocrine treatment; Letrozole; Trastuzumab; ADJUVANT CHEMOTHERAPY; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; TAMOXIFEN; HER-2/NEU; ARIMIDEX; SAFETY; PLUS; HER2;

D O I：

10.1016/j.breast.2011.07.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The eLEcTRA trial compared efficacy and safety of letrozole combined with trastuzumab to letrozole alone in patients with HER2 and hormone receptor (HR) positive metastatic breast cancer (MBC). Patients were randomized to either letrozole alone (arm A, n = 31) or letrozole plus trastuzumab (arm B, n = 26) as first-line treatment. Additional 35 patients with HER2 negative and HR positive tumors received letrozole alone (arm C). Median time to progression in arm A was 3.3 months compared to 14.1 months in arm B (hazard ratio 0.67; p = 0.23) and 15.2 months in arm C (hazard ratio 0.71; p = 0.03). Clinical benefit rate was 39% for arm A compared to 65% in arm B (odds ratio 2.99, 95% CI 1.01-8.84) and 77% in arm C (odds ratio 5.34, 95% CI 1.83-15.58). The eLEcTRA trial showed that the combination of letrozole and trastuzumab is a safe and effective treatment option for patients with HER2 positive and HR positive MBC. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：27 / 33

页数：7

共 50 条

[21] Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
Merriam, Priscilla
Sikov, William M.
BREAST CANCER-TARGETS AND THERAPY, 2011, 3 : 139 - 150
[22] Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Infante, Jeffrey R.
Yardley, Denise A.
Burris, Howard A., III
Greco, F. Anthony
Farley, Cindy P.
Webb, Charles
Spigel, David R.
Hainsworth, John D.
CLINICAL BREAST CANCER, 2009, 9 (01) : 23 - 28
[23] Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+advanced or metastatic breast cancer(MBC)
Riemsma, Rob
Forbes, Carol A.
Amonkar, Mayur M.
Lykopoulos, Konstantinos
Diaz, Jose R.
Kleijnen, Jos
Rea, Daniel W.
CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (08) : 1263 - 1279
[24] PertuzumabIn the First-Line Treatment of HER2-Positive Metastatic Breast Cancer
Gillian M. Keating
Drugs, 2012, 72 : 353 - 360
[25] Pertuzumab In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer
Keating, Gillian M.
DRUGS, 2012, 72 (03) : 353 - 360
[26] Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
Hua, Xin
Bi, Xi-Wen
Zhao, Jian-Li
Shi, Yan-Xia
Lin, Ying
Wu, Zhi-Yong
Zhang, Yuan-Qi
Zhang, Le-Hong
Zhang, An-Qing
Huang, Heng
Liu, Xin-Mei
Xu, Fei
Guo, Ying
Xia, Wen
Hong, Ruo-Xi
Jiang, Kui-Kui
Xue, Cong
An, Xin
Zhong, Yong-Yi
Wang, Shu-Sen
Huang, Jia-Jia
Yuan, Zhong-Yu
CLINICAL CANCER RESEARCH, 2022, 28 (04) : 637 - 645
[27] Everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic cancer: Evaluating synergy and overcoming resistance
Ballhausen, Alexej
Wheler, Jennifer J.
Karp, Daniel D.
Piha-Paul, Sarina A.
Fu, Siqing
Pant, Shubham
Tsimberidou, Apostolia M.
Hong, David S.
Subbiah, Vivek
Holley, Veronica R.
Huang, Helen J.
Brewster, Abeena M.
Koenig, Kimberly H.
Ibrahim, Nuhad K.
Meric-Bernstam, Funda
Janku, Filip
CANCER RESEARCH, 2020, 80 (04)
[28] Cardiac safety of trastuzumab in combination with epirubicin/cyclophosphamide as first-line therapy in patients with HER2-positive metastatic breast cancer
Untch, M.
Tjulandin, S.
Jonat, W.
Meerpohl, H.
Lichinitser, M.
Manikhas, G. M.
Jaenicke, F.
Muscholl, M.
Pauschinger, M.
Lehle, M.
EJC SUPPLEMENTS, 2007, 5 (04): : 216 - 216
[29] Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
Pier Paolo M. Berton Giachetti
Giuseppe Curigliano
Nature Reviews Clinical Oncology, 2024, 21 : 171 - 172
[30] Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
Giachetti, Pier Paolo M. Berton
Curigliano, Giuseppe
NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (03) : 171 - 172

← 1 2 3 4 5 →